Duopharma Biotech Bhd (KLSE:7148) — Market Cap & Net Worth
Market Cap & Net Worth: Duopharma Biotech Bhd (7148)
Duopharma Biotech Bhd (KLSE:7148) has a market capitalization of $297.06 Million (RM1.18 Billion) as of June 16, 2026. Listed on the KLSE stock exchange, this Malaysia-based company holds position #15022 globally and #173 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Duopharma Biotech Bhd's stock price RM1.23 by its total outstanding shares 961942451 (961.94 Million). Review debt load of Duopharma Biotech Bhd to assess the company's total debt and financial obligations.
Duopharma Biotech Bhd Market Cap History: 2015 to 2026
Duopharma Biotech Bhd's market capitalization history from 2015 to 2026. Data shows growth from $159.01 Million to $297.06 Million (5.77% CAGR).
Duopharma Biotech Bhd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Duopharma Biotech Bhd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.32x
Duopharma Biotech Bhd's market cap is 0.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.45x
Duopharma Biotech Bhd's market cap is 3.45 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $124.67 Million | $312.94 Million | $26.83 Million | 0.40x | 4.65x |
| 2017 | $164.01 Million | $467.99 Million | $42.46 Million | 0.35x | 3.86x |
| 2018 | $148.36 Million | $498.72 Million | $47.64 Million | 0.30x | 3.11x |
| 2019 | $230.02 Million | $576.46 Million | $55.27 Million | 0.40x | 4.16x |
| 2020 | $565.40 Million | $569.90 Million | $58.61 Million | 0.99x | 9.65x |
| 2021 | $384.05 Million | $639.17 Million | $65.68 Million | 0.60x | 5.85x |
| 2022 | $373.74 Million | $696.72 Million | $70.11 Million | 0.54x | 5.33x |
| 2023 | $297.25 Million | $704.73 Million | $52.65 Million | 0.42x | 5.65x |
| 2024 | $301.89 Million | $813.70 Million | $62.65 Million | 0.37x | 4.82x |
| 2025 | $301.89 Million | $931.69 Million | $87.46 Million | 0.32x | 3.45x |
Competitor Companies of 7148 by Market Capitalization
Companies near Duopharma Biotech Bhd in the global market cap rankings as of June 16, 2026.
Key companies related to Duopharma Biotech Bhd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Duopharma Biotech Bhd Historical Marketcap From 2015 to 2026
Between 2015 and today, Duopharma Biotech Bhd's market cap moved from $159.01 Million to $ 297.06 Million, with a yearly change of 5.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RM297.06 Million | -1.60% |
| 2025 | RM301.89 Million | 0.00% |
| 2024 | RM301.89 Million | +1.56% |
| 2023 | RM297.25 Million | -20.47% |
| 2022 | RM373.74 Million | -2.69% |
| 2021 | RM384.05 Million | -32.07% |
| 2020 | RM565.40 Million | +145.81% |
| 2019 | RM230.02 Million | +55.04% |
| 2018 | RM148.36 Million | -9.54% |
| 2017 | RM164.01 Million | +31.56% |
| 2016 | RM124.67 Million | -21.60% |
| 2015 | RM159.01 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Duopharma Biotech Bhd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $297.06 Million USD |
| MoneyControl | $297.06 Million USD |
| MarketWatch | $297.06 Million USD |
| marketcap.company | $297.06 Million USD |
| Reuters | $297.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more